Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the ...

DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the ...

Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Here's a quick look at what's been pushing up shares of Instil Bio and some of its challenges. Plus, I'll also measure the good news against the bad to see if everyday investors can reasonably expect ...

Instil was able to sell more shares and at a higher price than it initially planned. The Dallas-based company set preliminary IPO terms on Monday for an offering of 13.9 million shares in the range of ...

In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into a termination agreement with ImmuneOnco Biopharmaceuticals ...

Global registrational strategy in first-line triple-negative breast cancer (TNBC) Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC anticipated in late 2024 in ...

The Instil Bio Life Sciences Campus will be at 18404-18412 Oxnard Street in the neighborhood of Tarzana in the San Fernando Valley. CBRE said that, with clinical manufacturing operational, the recent ...